| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
| Share Statistics | RGC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,699.3 | $486.8 | 63% |
|
| Shares Out (Mil) | 494.7 | 42.8 | 88% |
|
| Institutional Ownership | 0.4% | 81.8% | 1% |
|
| Float (Mil) | 55.6 | 44.5 | 49% |
|
| Beta | 1.17 | 0.72 | 69% |
|
| Avg Daily Volume (000s) | 620 | 275 | 62% |
|
| Price Change (52-week) |
(53.1%) | 55.6% | 19% |
|
| Growth | RGC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (55.2%) | (2.0%) | 6% |
|
| EPS (5yr) | (43.1%) | 15.0% | 5 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | RGC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $392 | na |
|
| Net Income (TTM) (Mil) | ($12) | ($11) | 28% |
|
| EPS (TTM) | ($0.024) | ($0.700) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | ($8) | ($7) | 22% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | $4,707 | $494 | 62% |
|
| Valuation | RGC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 248.67 | 2.17 | 100% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | RGC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.3% | na |
|
| ROA | (114.2%) | (22.0%) | 5% |
|
| ROE | (128.5%) | (20.6%) | 7% |
|
| Liabilities to Assets | 9.4% | 32.2% | 6% |
|
| F-Score | 3 | 3 | 18% |
|
Regencell Bioscience Holdings Limited did not pass any screens on 10/27/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors
